{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:36:25Z","timestamp":1792082185766,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Child and Adolescent Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.chc.2008.06.002","type":"journal-article","created":{"date-parts":[[2008,9,7]],"date-time":"2008-09-07T15:04:56Z","timestamp":1220799896000},"page":"739-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Pharmacotherapy of Irritability in Pervasive Developmental Disorders"],"prefix":"10.1016","volume":"17","author":[{"given":"Kimberly A.","family":"Stigler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chc.2008.06.002_bib1","series-title":"Diagnostic and statistical manual of mental disorders. 4th edition, text revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.chc.2008.06.002_bib2","series-title":"Understanding autism: from basic neuroscience to treatment","first-page":"417","article-title":"Pharmacological treatments","author":"McDougle","year":"2006"},{"key":"10.1016\/j.chc.2008.06.002_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/jpepsy\/2.4.153","article-title":"Current status of drug research and treatment with autistic children","volume":"2","author":"Campbell","year":"1977","journal-title":"J Pediatr Psychol"},{"key":"10.1016\/j.chc.2008.06.002_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0002-7138(09)61017-7","article-title":"A comparison of haloperidol and behavior therapy and their interaction in autistic children","volume":"17","author":"Campbell","year":"1978","journal-title":"J Am Acad Child Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib5","first-page":"753","article-title":"Children's Psychiatric Rating Scale (scoring)","volume":"21","author":"Fish","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.chc.2008.06.002_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0002-7138(09)60969-9","article-title":"Behavioral effects of haloperidol in young autistic children","volume":"19","author":"Cohen","year":"1980","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","article-title":"Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms","volume":"141","author":"Anderson","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02211843","article-title":"The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children","volume":"19","author":"Anderson","year":"1989","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.002_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004583-198901000-00016","article-title":"Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration","volume":"28","author":"Perry","year":"1989","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study","volume":"36","author":"Campbell","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.chc.2008.06.002_bib12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/ajp.153.5.738a","article-title":"Clinical effects of clozapine on autistic disorder","volume":"153","author":"Zuddas","year":"1996","journal-title":"Am J\u00a0Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2008.06.002_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4088\/JCP.v62n0612h","article-title":"Clozapine in the treatment of aggression in an adolescent with autistic disorder","volume":"62","author":"Chen","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib14","first-page":"340","article-title":"Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior","volume":"26","author":"Gobbi","year":"2001","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.chc.2008.06.002_bib15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chc.2008.06.002_bib16","first-page":"485","article-title":"The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects","volume":"5","author":"Aman","year":"1985","journal-title":"Am J Ment Defic"},{"key":"10.1016\/j.chc.2008.06.002_bib17","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the Research Units on Pediatric Psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0002-7138(09)60610-5","article-title":"A scale for rating symptoms of patients with the syndrome of autism in real life settings","volume":"25","author":"Freeman","year":"1986","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","article-title":"Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity","volume":"36","author":"Scahill","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib20","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Am J\u00a0Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study","volume":"44","author":"Troost","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib22","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.chc.2008.06.002_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF02408436","article-title":"Toward objective classification of childhood autism: childhood autism rating scale (CARS)","volume":"10","author":"Schopler","year":"1980","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.002_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","article-title":"Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial","volume":"17","author":"Miral","year":"2008","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo-controlled, double-blind study","volume":"21","author":"Nagaraj","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.chc.2008.06.002_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy","volume":"16","author":"Luby","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004714-199902000-00008","article-title":"Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study","volume":"19","author":"Potenza","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00004583-200108000-00009","article-title":"Olanzapine versus haloperidol in children with autistic disorder: an open pilot study","volume":"40","author":"Malone","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200210000-00003","article-title":"Open-label study of olanzapine in children with pervasive developmental disorder","volume":"22","author":"Kemner","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/cap.1999.9.99","article-title":"Open-label quetiapine in the treatment of children and adolescents with autistic disorder","volume":"9","author":"Martin","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/1044546041649129","article-title":"Quetiapine in nine youths with autistic disorder","volume":"14","author":"Findling","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib33","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.4088\/JCP.v65n1115","article-title":"A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders","volume":"65","author":"Corson","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10803-005-3306-1","article-title":"Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders","volume":"35","author":"Hardan","year":"2005","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.chc.2008.06.002_bib35","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004583-200208000-00010","article-title":"Case series: use of ziprasidone for maladaptive symptoms in youths with autism","volume":"41","author":"McDougle","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4088\/JCP.v65n0119","article-title":"The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment","volume":"65","author":"Cohen","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2008.06.002_bib37","first-page":"779","article-title":"Ziprasidone in adolescents with autism: an open-label pilot study","volume":"17","author":"Malone","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cap.2004.14.455","article-title":"Case report: aripiprazole for maladaptive behavior in pervasive developmental disorder","volume":"14","author":"Stigler","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/cap.2006.16.549","article-title":"Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities","volume":"16","author":"Valicenti-McDermott","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib40","series-title":"Aripiprazole in Asperger's disorder and pervasive developmental disorder not otherwise specified: a 14-week prospective, open-label study","author":"Stigler","year":"2007"},{"key":"10.1016\/j.chc.2008.06.002_bib41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder","volume":"12","author":"Jaselskis","year":"1992","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2008.06.002_bib42","first-page":"77","article-title":"A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism","volume":"53","author":"Fankhauser","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.chc.2008.06.002_bib43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/1044546041649084","article-title":"Guanfacine treatment of hyperactivity and inattention in autism: a retrospective analysis of 80 cases","volume":"14","author":"Posey","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/cap.1994.4.201","article-title":"Lithium augmentation of fluvoxamine in autistic disorder: a case report","volume":"4","author":"Epperson","year":"1994","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"10.1016\/j.chc.2008.06.002_bib45","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4088\/JCP.v62n07a05","article-title":"An open trial of divalproex sodium in autism spectrum disorders","volume":"62","author":"Hollander","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2008.06.002_bib46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2008.06.002_bib47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/s-2008-1073041","article-title":"Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non\u2013seizure-related benefits","volume":"25","author":"Uvebrant","year":"1994","journal-title":"Neuropediatrics"},{"issue":"2","key":"10.1016\/j.chc.2008.06.002_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Belsito","year":"2001","journal-title":"J Autism Dev Disord"},{"issue":"10","key":"10.1016\/j.chc.2008.06.002_bib49","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.braindev.2006.05.004","article-title":"Topiramate in children with autistic spectrum disorders","volume":"28","author":"Mazzone","year":"2006","journal-title":"Brain Dev"},{"issue":"4","key":"10.1016\/j.chc.2008.06.002_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004703-200208000-00006","article-title":"Levetiracetam in autistic children: an open-label study","volume":"23","author":"Rugino","year":"2002","journal-title":"J Dev Behav Pediatr."},{"issue":"6","key":"10.1016\/j.chc.2008.06.002_bib51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int Clin Psychopharmacol"}],"container-title":["Child and Adolescent Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499308000461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499308000461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:38:32Z","timestamp":1760999912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056499308000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1056499308000461"],"URL":"https:\/\/doi.org\/10.1016\/j.chc.2008.06.002","relation":{},"ISSN":["1056-4993"],"issn-type":[{"value":"1056-4993","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy of Irritability in Pervasive Developmental Disorders","name":"articletitle","label":"Article Title"},{"value":"Child and Adolescent Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chc.2008.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}